I2I Phase I: A Portable Blood Group Typing Analyzer

I2I 第一阶段：便携式血型分型分析仪

• 批准号: 566842-2021
• 负责人: Wheeler, Aaron
• 金额: $ 9.11万
• 依托单位: University of Toronto
• 依托单位国家: 加拿大
• 项目类别: Idea to Innovation
• 财政年份: 2021
• 资助国家: 加拿大
• 起止时间: 2021-01-01 至 2022-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=728736
• 关键词: I2I; Phase; Portable; Blood; Group

Hemorrhage is the third leading cause of death among trauma patients. A transfusion is needed to replenish the patient's lost blood; however, prior to transfusion, physicians must determine the patient's blood type to administer blood from a compatible donor. In high stakes environments such as a trauma setting every second is critical and therefore doctors are in need for fast and reliable methods to monitor the hemorrhaging patient. Currently, hospitals rely on large batch processing systems, dedicated to each test or subset of tests (e.g. blood-grouping and hematological tests), which introduce large delays between the sample collection and the results' release. While physicians wait for these results, they must use universal blood products that are in short supply. To address this issue, the microfluidics community has developed point-of-care tests, but those that have made it to market have not been adopted because of errors caused by manual processing and analysis "by eye." This proposal aims to prove the concept of an autonomous, low-cost blood analyzer, used to provide healthcare professionals with access to real time and reliable results. The solution described here is based on an advanced liquid handling technology, called digital microfluidics (DMF), which uses an array of electrodes to manipulate discrete droplets. DMF enables complete automation of blood group testing, with results that are in 100% concordance with the gold standard method. The results are available in 6 minutes from a shoebox sized, battery-powered instrument that can be operated at the point of care. This I2I Phase 1 grant will allow us to explore options to bring the cost of consumable cartridges down to competitive levels, as a step toward commercialization. We envision that this platform will become an essential medical monitoring device for physicians that seek fast and reliable blood analyses at the point of care, helping them provide best-in-class care for Canadians and others around the world.

出血是创伤患者死亡的第三大原因。需要输血来补充患者失去的血液;然而，在输血之前，医生必须确定患者的血型，以便从相容的供体处输血。在高风险的环境中，例如创伤环境，每一秒都是至关重要的，因此医生需要快速可靠的方法来监测正在康复的患者。目前，医院依赖于大批量处理系统，专用于每个测试或测试子集（例如，血型和血液学测试），这在样本收集和结果发布之间引入了很大的延迟。在医生等待这些结果的同时，他们必须使用供应短缺的通用血液制品。为了解决这个问题，微流体社区已经开发了即时检测，但是那些已经进入市场的检测还没有被采用，因为人工处理和“肉眼”分析造成的错误。“该提案旨在证明自主、低成本血液分析仪的概念，用于为医疗保健专业人员提供真实的时间和可靠的结果。这里描述的解决方案是基于一种先进的液体处理技术，称为数字微流体（DMF），它使用电极阵列来操纵离散的液滴。DMF可实现血型检测的完全自动化，结果与金标准方法100%一致。结果可在6分钟内从一个鞋盒大小的电池供电的仪器，可以在护理点操作。这笔I2 I第一阶段的赠款将使我们能够探索将耗材盒的成本降低到具有竞争力的水平的选择，作为迈向商业化的一步。我们设想，该平台将成为寻求在护理点进行快速可靠血液分析的医生必不可少的医疗监测设备，帮助他们为加拿大人和世界各地的其他人提供一流的护理。